pharmaphorum2d
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...
pharmaphorum2y
FDA knocks back MEI's plans for drug in troubled PI3K class
MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K inhibitor zandelisib in B cell lymphoma, after being "discouraged" by the FDA from making the ...
Relay Therapeutics: Positioned for Success with Best-in-Class PI3Kα Inhibitor RLY-2608
In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report), with a ...
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...
Eli Lilly and Company: Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Ka inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...